^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

006 | DETERMINANTS OF RESISTANCE TO ENGINEERED T-CELL THERAPIES TARGETING CD19 IN LYMPHOMA

Published date:
06/09/2021
Excerpt:
...analysis to patients receiving Axicabtagene Ciloleucel (axi-cel) to identify determinants of resistance...We identified 100.5 mutations/case, which was similar to a cohort of 136 untreated DLBCL patients....Additionally, genomic alterations in several genes, including CD19, CD58, PAX5 and IRF8 are associated with inferior outcomes.